{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:12:56Z","timestamp":1790035976441,"version":"4.0.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.juro.2010.03.147","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T00:47:06Z","timestamp":1277081226000},"page":"616-622","source":"Crossref","is-referenced-by-count":58,"title":["A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder"],"prefix":"10.1097","volume":"184","author":[{"given":"Tara L.","family":"Frenkl","sequence":"first","affiliation":[{"name":"Merck & Co, Inc., Whitehouse Station, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc., Whitehouse Station, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Reiss","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc., Whitehouse Station, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Seltzer","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc., Whitehouse Station, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc., Whitehouse Station, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Green","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc., Whitehouse Station, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2010.03.147_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2010.03.147_bib2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed?","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.03.147_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2010.03.147_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2005.05889.x","article-title":"Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries","volume":"97","author":"Irwin","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.03.147_bib5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1185\/030079904125003593","article-title":"The wet patient: understanding patients with overactive bladder and incontinence","volume":"20","author":"Serels","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.juro.2010.03.147_bib6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MOU.0b013e32832ce8a4","article-title":"Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence","volume":"19","author":"Andersson","year":"2009","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.juro.2010.03.147_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.03.147_bib8","series-title":"Tolterodine tartrate extended release capsules","author":"Tolterodine","year":"2009"},{"key":"10.1016\/j.juro.2010.03.147_bib9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1111\/j.1471-4159.1993.tb03484.x","article-title":"Tachykinin receptors: a radioligand binding perspective","volume":"60","author":"Mussap","year":"1993","journal-title":"J Neurochem"},{"key":"10.1016\/j.juro.2010.03.147_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1046\/j.1460-9568.2003.02600.x","article-title":"Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain","volume":"17","author":"Caberlotto","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.juro.2010.03.147_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1152\/physrev.1993.73.2.229","article-title":"Neurotransmitter functions of mammalian tachykinins","volume":"73","author":"Otsuka","year":"1993","journal-title":"Physiol Rev"},{"key":"10.1016\/j.juro.2010.03.147_bib12","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0022-5347(05)66405-1","article-title":"Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats","volume":"165","author":"Abdel-Gawad","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.03.147_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2004.05017.x","article-title":"Mechanisms of neurokinin A- and substance P-induced contractions in rat detrusor smooth muscle in vitro","volume":"94","author":"Quinn","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.03.147_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-2999(94)90501-0","article-title":"Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats","volume":"259","author":"Lecci","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.juro.2010.03.147_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1464-410X.1992.tb15790.x","article-title":"Increase in presumptive sensory nerves of the urinary bladder in idiopathic detrusor instability","volume":"70","author":"Moore","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2010.03.147_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0014-2999(00)00177-1","article-title":"Effects of TAK-637, a tachykinin receptor antagonist, on the micturition reflex in guinea pigs","volume":"395","author":"Doi","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.juro.2010.03.147_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2005.11.021","article-title":"Tachykinins: role in detrusor overactivity?","volume":"49","author":"Andersson","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.03.147_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/10790268.2006.11753853","article-title":"Normal ranges of variability for urodynamic studies of neurogenic bladders in spinal cord injury","volume":"29","author":"Chou","year":"2006","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.juro.2010.03.147_bib19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2005.04.012","article-title":"Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial","volume":"48","author":"Silva","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.03.147_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00005392-199907000-00002","article-title":"Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder","volume":"162","author":"Chancellor","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.03.147_bib21","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.juro.2006.08.018","article-title":"Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence","volume":"176","author":"Green","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.03.147_bib22","unstructured":"Data on file, Merck & Co., Inc., Rahway, New Jersey 2009."},{"key":"10.1016\/j.juro.2010.03.147_bib23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0090-4295(02)02505-0","article-title":"Measurement characteristics of a voiding diary for use by men and women with overactive bladder","volume":"61","author":"Brown","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.juro.2010.03.147_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","article-title":"Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial","volume":"105","author":"Herschorn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.03.147_bib25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.biopsych.2004.02.007","article-title":"Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant","volume":"55","author":"Bergstrom","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.juro.2010.03.147_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1532-5415.2002.50203.x","article-title":"Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients","volume":"50","author":"Zinner","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.juro.2010.03.147_bib27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0022-5347(05)64567-3","article-title":"Does gender or age affect the efficacy and safety of tolterodine?","volume":"168","author":"Michel","year":"2002","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710032751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710032751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2010.03.147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:46:08Z","timestamp":1651196768000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2010.03.147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1016\/j.juro.2010.03.147"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2010.03.147","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}